Clinical significance of atrial fibrillation detected by cardiac implantable electronic devices

Heart Rhythm

Volumn 11, Issue 4, 2014, Pages 719-724

  DeCicco, Anthony E ^a   Finkel, Jonathan B ^a   Greenspon, Arnold J ^a   Frisch, Daniel R ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cardiac implantable electronic device; Cardiac resynchronization therapy; Implantable cardioverter defibrillator; Pacemaker

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC IMPLANTABLE ELECTRONIC DEVICE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE DURATION; DIZZINESS; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HOLTER MONITORING; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; PHYSICAL EXAMINATION; POPULATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINUS NODE DISEASE; THORAX PAIN; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; ARTERY EMBOLISM; ATRIAL FIBRILLATION; CARDIAC IMPLANT; COMPLICATION; ELECTRONICS; ORAL DRUG ADMINISTRATION; PROSTHESES AND ORTHOSES; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRONICS, MEDICAL; HUMANS; PROSTHESES AND IMPLANTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STROKE;

EID: 84896901708     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.01.001     Document Type: Article

References (27)

1. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129.
2. Faroogi FM, Talsania S, Hamid S, Rinaldi CA. Extraction of cardiac rhythm devices: indications, techniques, and outcomes for the removal of pacemaker and defibrillator leads. Int J Clin Pract 2010;64:1140-114-7.
3. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). Circulation 2003;107:1614-1619. (Pubitemid 36397330)
4. Mittal S, Stein K, Gilliam FR, Kraus SM, Meyer TE, Christman SA. Frequency, duration, and predictors of newly-diagnosed atrial. brillation following dualchamber pacemaker implantation in patients without a previous history of atrial fibrillation. Am J Cardiol 2008;102:450-453.
5. Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm 2011;8:342-348.
6. Borleffs CJW, Ypenburg C, van Bommel RJ, et al. Clinical importance of new-onset atrial fibrillation after cardiac resynchronization therapy. Heart Rhythm 2009;6:305-310.
7. Cheung JW, Keating RJ, Stein KM, et al. Newly detected atrial fibrillation following dual chamber pacemaker implantation. J Cardiovasc Electrophysiol 2006;17:1323-1328. (Pubitemid 44808552)
8. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;20:241-248.
9. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-480.
10. Capucci A, Santini M, Padeletti L, et al. Monitored atrial fibrillation duration predicts arterial embolism events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemaker. J Am Coll Cardiol 2005;46:1913-1920. (Pubitemid 41579816)
11. Ziegler PD, Glotzer TV, Daoud EG, et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012;110:1309-1314.
12. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Circulation 2006;114:e257-e354. (Pubitemid 44252297)
13. Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation 2006;114:11-17. (Pubitemid 44305269)
14. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25. (Pubitemid 44305270)
15. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009;301:2571-2577.
16. Kaufman ES, Israel CW, Nair GM, et al. Positive predictive value of devicedetected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241-1246.
17. Glotzer TV. To the editor - is manual adjudication of AF episodes detected by implanted devices required? Heart Rhythm 2012;9:e17-e18.
18. Purerfellner H, Gillis AM, Holbrook R, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004;27:983-992. (Pubitemid 38970216)
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870. (Pubitemid 32537350)
20. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
21. Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study. Circulation 2012;125:2298-2307.
22. Ip J, Waldo AL, Lip GYH, et al. for the IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design and clinical characteristics of the initially enrolled cohort: the IMPACT study. Am Heart J 2009;158:364-370.
23. Camm AJ, Lip GY, Caterina De, et al. for the ESC Committee for Practice Guidelines-CPG. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
24. Fuster V, Chinitz JS. Net clinical benefit of warfarin: extending the reach of antithrombotic therapy for atrial fibrillation. Circulation 2012;125:2285-2287.
25. Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 2013;61:852-860.
26. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008;51:1790-1793. (Pubitemid 351608489)
27. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011;8:1416-1423.